Meridian Bioscience (VIVO) Misses Q1 EPS by 5c; Lowers Outlook, Cuts Dividend
Get Alerts VIVO Hot Sheet
Revenue Growth %: -100.0%
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
TOWN, NRIM, GCBC, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.15, $0.05 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $51.1 million.
GUIDANCE:
Meridian Bioscience sees FY2017 EPS of $0.64-$0.69, versus the consensus of $0.82. Meridian Bioscience sees FY2017 revenue of $193-199 million, versus the consensus of $206.1 million.
Revised the fiscal 2017 annual indicated cash dividend rate to $0.50 per share, and declared the regular quarterly cash dividend of $0.125 per share for the first quarter of fiscal 2017 (annual indicated rate of $0.50 per share);
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Towne Bank (TOWN) Reports In-Line Q1 EPS
- SLM (SLM) Tops Q1 EPS by 20c; offers guidance
Create E-mail Alert Related Categories
Dividends, Earnings, Guidance, Hot GuidanceRelated Entities
Dividend, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!